Late complications of immune deviation therapy in a nonhuman primate.
about
Heat shock protein bystander antigens for peptide immunotherapy in autoimmune diseaseRestoring immune tolerance in neuromyelitis optica: Part IThe immunology of stroke: from mechanisms to translationNeurobehavioral development of common marmoset monkeys.Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelinationAn unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.Long term immunologic consequences of experimental stroke and mucosal tolerance.Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis.Therapeutic strategies in multiple sclerosis. I. ImmunotherapySuperantigens: mechanisms by which they may induce, exacerbate and control autoimmune diseases.Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation.Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?α-MSH: a potential neuroprotective and immunomodulatory agent for the treatment of stroke.Immunoadsorption patients with multiple sclerosis: an open-label pilot study.Preclinical assessment of stem cell therapies for neurological diseases.Antigen-based immune modulation: DNA vectors and beyond.Gene therapy in autoimmune, demyelinating disease of the central nervous system.Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network.T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy.Time course and cellular localization of interleukin-10 mRNA and protein expression in autoimmune inflammation of the rat central nervous systemCentral role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesionsThe Charcot Lecture | beating MS: a story of B cells, with twists and turnsPeptide-based therapeutic vaccines for allergic and autoimmune diseases.Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate diseaseCan we vaccinate against Type 1 diabetes?Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitisOptic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease.Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia.Amelioration of experimental autoimmune encephalomyelitis in IL-4Ralpha-/- mice implicates compensatory up-regulation of Th2-type cytokines.
P2860
Q27008837-626B0E74-C0D4-400E-927B-A6055ADDDD51Q28072382-9322397A-ED98-4AD0-B66B-03F35428621BQ29620066-2AEBD8FD-0EA0-427E-A29C-18188BDDB29DQ30375150-7DFFDEF6-213B-491A-896F-D207DDA80FE7Q31076579-FD565FED-83E2-4998-81DF-2D016F473F52Q32063760-0F79708D-0864-4984-BF15-E708C1A954D3Q33631679-AA4E5991-628C-42FD-9D8A-74CAD1C57BF6Q33713307-D282FDDE-106A-4BA7-B24A-62F73D3CA6C2Q33798254-4ACB3972-BA56-4B04-9442-75340367C735Q33805908-C26AD8A3-6F95-4A8A-84F8-DB29C394CA76Q33835115-F42B690D-6C38-4BA4-BB6D-B04309B26B83Q33838467-351F9C6E-2ADA-400A-896E-9EB5B7F40349Q33901936-7D64332F-3A39-4339-8A04-824C6A93D516Q34082782-7A73F26D-E8E8-4FFD-8924-58610A0A57D4Q34307160-358F6AB8-6895-433F-9224-EFD23C65EFF6Q34398673-D7EE3331-3828-4FD0-A596-892EB1B89B72Q34567725-F6B851F0-D33A-4B63-9368-B0BB8CC1AE0CQ34627621-09C387DE-6396-41F2-A4FC-5D775DA09D05Q34650883-3C3E8C5D-672D-49B1-8267-01EB42FEA85EQ34786764-37D409A2-58C6-412D-B6CD-3BEC850CFBA8Q35040861-64803DA6-9227-4A11-B46A-3CF449310E55Q35122159-81B15988-9777-4E3D-B296-07733EF67300Q35193544-27E423A4-D042-44A1-A213-AC0E1C3CDC3BQ35558638-62F4388D-8B36-44D7-9F50-8A00A505AACAQ35753349-E0ECD9A7-E2F5-4245-884B-4E8AA87B9C3EQ35764514-5A274CA5-9126-4B1F-A2F2-72D5F17878BEQ36072420-BAB0C3EA-038F-44C9-BC32-E313719E7E91Q36086475-C3DAB748-559A-426A-A646-D61877BA4C76Q36090197-D4717D48-CEDB-4EC7-A919-8C458C8985EDQ36179710-19EAE540-6966-4799-A60A-C8999B9865F8Q36284342-0E7EB2E2-78C9-42FF-899F-A7FE50418B07Q36296386-576090CC-84DE-48C4-AA18-97337F3E348FQ36327367-B4AAD859-426E-46C1-ADA7-FD343C1EA980Q36327666-7F69746E-20A6-41DB-8796-D0B13D151F04Q36368042-E1F934FE-1310-4202-9AA5-912AC3BA7CE5Q36370956-7F5ED5ED-4AE4-46D6-8FAB-5E12A8F06866Q36380402-7A466BD0-56A7-473D-8109-A4754695CFD0Q36415576-B208DD75-26C9-4E84-949C-5882BDD36F56Q36599073-8E4629CD-5590-43B6-BFA7-FF02F2572ED8Q36734874-EDA21C1C-A539-4DEE-9182-CAFCFC1A4689
P2860
Late complications of immune deviation therapy in a nonhuman primate.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Late complications of immune deviation therapy in a nonhuman primate.
@en
Late complications of immune deviation therapy in a nonhuman primate.
@nl
type
label
Late complications of immune deviation therapy in a nonhuman primate.
@en
Late complications of immune deviation therapy in a nonhuman primate.
@nl
prefLabel
Late complications of immune deviation therapy in a nonhuman primate.
@en
Late complications of immune deviation therapy in a nonhuman primate.
@nl
P2093
P2860
P1433
P1476
Late complications of immune deviation therapy in a nonhuman primate.
@en
P2093
Rosenberg DP
Villinger F
P2860
P304
P356
10.1126/SCIENCE.274.5295.2054
P407
P577
1996-12-01T00:00:00Z